IL6 and infection: Compared with non-anti-IL-6 bDMARDs, the rate of infections recorded as ICD-10 codes in secondary care data was significantly higher in anti-IL-6 bDMARD-treated patients before treatment [difference 8.8% (95% CI 1.1.